L. Burton

发表

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Jane Fridlyand, Antoni Ribas, Timothy R. Wilson, 2012, Nature.

Manufacturing of Large Numbers of Patient-specific T Cells for Adoptive Immunotherapy: An Approach to Improving Product Safety, Composition, and Production Capacity

S. Forman, M. Jensen, L. Burton, 2007, Journal of immunotherapy.

Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.

S. Forman, M. Jensen, S. Olivares, 2006, Cytotherapy.

Elevated Levels of BRAFV600 Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma.

P. Ascierto, J. Larkin, J. Sosman, 2018, JCO precision oncology.

Companion Diagnostics & Cancer Biomarkers HGFasaCirculatingBiomarker ofOnartuzumabTreatment in Patients with Advanced Solid Tumors

G. Hampton, P. Hegde, M. Merchant, 2013 .

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.

Adam R. Johnson, C. Eigenbrot, A. Estevez, 2016, ACS chemical biology.

Resistance of Natural Killer and T Cells to Venetoclax Allows for Combination Treatment with Cancer Immunotherapy Agents

M. Belvin, L. Molinero, D. Sampath, 2018, Blood.

HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors

G. Hampton, P. Hegde, M. Merchant, 2013, Molecular Cancer Therapeutics.

HGFasaCirculatingBiomarkerofOnartuzumabTreatmentin Patients with Advanced Solid Tumors

G. Hampton, P. Hegde, M. Merchant, 2013 .

HGFasaCirculatingBiomarker ofOnartuzumabTreatment in Patients with Advanced Solid Tumors

G. Hampton, P. Hegde, M. Merchant, 2013 .